SUPRIYA Stock Overview
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for SUPRIYA from our risk checks.
Supriya Lifescience Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹410.55 |
| 52 Week High | ₹424.00 |
| 52 Week Low | ₹215.20 |
| Beta | 0.25 |
| 1 Month Change | 8.17% |
| 3 Month Change | 38.82% |
| 1 Year Change | 85.81% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 5.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| SUPRIYA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.3% | 0.9% | 1.0% |
| 1Y | 85.8% | 57.7% | 44.8% |
Return vs Industry: SUPRIYA exceeded the Indian Pharmaceuticals industry which returned 57.7% over the past year.
Return vs Market: SUPRIYA exceeded the Indian Market which returned 44.8% over the past year.
Price Volatility
| SUPRIYA volatility | |
|---|---|
| SUPRIYA Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in IN Market | 10.0% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: SUPRIYA's share price has been volatile over the past 3 months.
Volatility Over Time: SUPRIYA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 392 | Rajeev Jain | www.supriyalifescience.com |
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. It offers anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, and anti-malarial products, as well as vitamins and xanthine derivatives. The company was founded in 1987 and is headquartered in Mumbai, India.
Supriya Lifescience Limited Fundamentals Summary
| SUPRIYA fundamental statistics | |
|---|---|
| Market cap | ₹33.04b |
| Earnings (TTM) | ₹1.20b |
| Revenue (TTM) | ₹5.54b |
27.4x
P/E Ratio6.0x
P/S RatioIs SUPRIYA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SUPRIYA income statement (TTM) | |
|---|---|
| Revenue | ₹5.54b |
| Cost of Revenue | ₹2.26b |
| Gross Profit | ₹3.28b |
| Other Expenses | ₹2.08b |
| Earnings | ₹1.20b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 14.96 |
| Gross Margin | 59.18% |
| Net Profit Margin | 21.72% |
| Debt/Equity Ratio | 0.8% |
How did SUPRIYA perform over the long term?
See historical performance and comparison